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Abstract Volatile anesthetics modulate a variety of physiolo-
gical and pathophysiological responses including hypoxic re-
sponses. Hypoxia-inducible factor 1 (HIF-1) is a transcription
factor that mediates cellular and systemic homeostatic responses
to reduced O2 availability in mammals, including erythropoiesis,
angiogenesis, and glycolysis. We demonstrate for the first time
that the volatile anesthetic halothane blocks HIF-1 activity and
downstream target gene expressions induced by hypoxia in the
human hepatoma-derived cell line, Hep3B. Halothane reversibly
blocks hypoxia-induced HIF-1K protein accumulation and
transcriptional activity at clinically relevant doses. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Volatile anesthetics mediate a variety of biological e¡ects,
most notably hypnotic e¡ects. In addition to their hypnotic
e¡ects on the central nervous system, volatile anesthetics af-
fect the cardiovascular and immune systems by modulating
vascular tone, cardiac contraction, and cytokine production.
A large number of studies have demonstrated that volatile
anesthetics directly a¡ect ligand-gated ion channels, including
glutamate receptors, nicotinic acetylcholine receptors and Q-
aminobutyric acid A receptors, as well as voltage-gated ion
channels, including Na, K, and Ca2 channels. In addition
to plasma membrane ion channels intracellular proteins such
as protein kinase C have been shown to be target molecules of
anesthetics [1].
Hypoxic stress induces a series of adaptive responses that
include alterations of metabolism and gene expression [2].
When availability of oxygen is limited, expression of genes
encoding components of the electron transport chain is re-
pressed, while transcription of genes encoding enzymes of
the glycolytic pathway is activated. Levels of erythropoietin,
the primary growth factor for erythroid progenitor cells and,
therefore, a major physiologic regulator of O2 supply in mam-
mals, increase several hundredfold in rodent liver and kidney
in response to hypoxia or anemia. The genes, including genes
encoding vascular endothelial growth factor (VEGF) and in-
ducible nitric oxide synthase, are also inducibly expressed in
response to hypoxia. Multiple hypoxic responses requiring
gene expression are under the control of the transcriptional
activator hypoxia-inducible factor 1 (HIF-1) which is a central
component in the hypoxic response pathway [3,4].
HIF-1 is a heterodimer consisting of HIF-1K and HIF-1L
subunits [3]. To activate transcription of target genes, HIF-1K
dimerizes with HIF-1L and the heterodimer binds to DNA at
sites represented by the consensus sequence 5P-RCGTG-3P.
The HIF-1 binding site is present within a hypoxia-responsive
element (HRE), a cis-acting transcriptional regulatory se-
quence that can be located within 5P-£anking, 3P-£anking, or
intervening sequences of target genes [3]. Targets of HIF-1
include genes whose protein products are involved in angio-
genesis, energy metabolism, erythropoiesis, cell proliferation
and death, vascular remodeling, and wound healing [5].
Halothane, which is the prototype of modern volatile anes-
thetics and is still widely used in clinical settings and animal
experiments, has been demonstrated to modulate respiratory
function and vascular tone during hypoxia. But so far, to the
best of our knowledge, there are no studies on the modulation
of hypoxia-induced gene regulation by volatile anesthetics. In
this study, using an established cell line derived from a human
hepatocellular carcinoma, Hep3B, we demonstrate that halo-
thane over a range of clinically relevant doses reversibly sup-
presses HIF-1 activation.
2. Materials and methods
2.1. Cell culture and reagents
The human hepatocellular carcinoma-derived cell line, Hep3B, was
kindly provided by Dr. Fujii-Kuriyama (Tohoku University, Japan)
[6]. Cells were maintained in modi¢ed Eagle’s medium with Earle’s
salts and 10% fetal bovine serum (Life Technologies). CoCl2 and
desferrioxamine (DFX) were obtained from Sigma. Halothane was
obtained from Takeda Chemical Industries (Osaka, Japan).
2.2. Plasmid construction
Reporter plasmid p2.1 harboring a 68-bp HRE from the human
enolase 1 (ENO1) gene inserted upstream of an SV40 promoter and
luciferase coding sequences and its HRE mutant, p2.4, have been
described previously [7]. Reporter plasmid P11w harboring a 47-bp
HRE from the human VEGF gene and its HRE mutant P11m have
been described previously [8]. Expression plasmid pGAL4-HIF-
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1K(531^826) has been described [9]. Reporter construct ptk-GALpx3-
LUC containing three copies of GAL4 binding sites in front of a
minimal thymidine kinase promoter and pCMV-GAL4-VP16 were
kindly provided by the late Dr. Kazuhiko Umesono (Kyoto Univer-
sity, Kyoto, Japan) [10]. The L-galactosidase expression plasmid,
pSV40-L-galactosidase, was obtained from Promega.
2.3. Hypoxic treatment
Cells were maintained in a multi-gas incubator (APMW-36, Astec,
Japan) and were exposed to hypoxia (1% O2, 5% CO2, 94% N2) with
or without halothane through a vaporizer [6]. The concentrations of
O2 and halothane in the incubator were monitored during treatment
with an anesthetic gas monitor (Type 1304, Bru«el and Kj×r, N×rum,
Denmark) that was calibrated before each study with a commercial
standard gas (47% O2, 5.6% CO2, 47% N2O, 2.05% sulfur hexa£uor-
ide). The anesthetic concentration in the medium was measured by gas
chromatography (Hewlett Packard, 5890A, Palo Alto, CA, USA) as
described previously [11].
2.4. Immunoblot assays of HIF-1K
Nuclear extracts were prepared following an established protocol
[9]. Aliquots were fractionated by SDS^PAGE and subjected to im-
munoblot assay using protein G-puri¢ed mouse monoclonal antibody
H1K67 (Novus Biologicals) at 1:1000 dilution [12,13]. Signal was de-
veloped using ECL-Plus reagents (Amersham).
2.5. Reporter gene assays
Reporter gene assays were performed following a protocol de-
scribed previously [10,13^15]. The relative fold induction of luciferase
activity was calculated after dividing the luciferase activity by L-ga-
lactosidase activity. Each experiment was done at least two times in
triplicate and data from a representative experiment was shown.
2.6. Statistical analysis
Statistical signi¢cance between two groups was tested using the
unpaired Student’s t-test. Di¡erences were considered statistically sig-
ni¢cant at a value of P6 0.05.
3. Results
3.1. Halothane blocks hypoxia-induced HIF-1-dependent gene
expression
To examine the e¡ect of halothane on hypoxia-induced
HIF-1 activity, Hep3B cells were subjected to reporter assay
using p2.1 containing an HRE from the ENO1 gene. Cells
were exposed to 20% or 1% O2 for 16 h with or without 1%
halothane and then subjected to luciferase assays. Halothane
suppressed hypoxia-induced reporter gene transcription in a
dose-dependent manner (Fig. 1A, upper panel). Halothane
also suppressed hypoxia-induced gene expression dependent
on a VEGF-derived HRE (Fig. 1A, lower panel). In both
reporter systems, the suppressive e¡ect of halothane was max-
imal at a concentration of 1%. Halothane did not signi¢cantly
a¡ect gene expression in cells exposed to 20% O2. It also did
not a¡ect gene expression of p2.4 or P11m, which contain
mutations that prevent HIF-1 binding. Halothane did not
signi¢cantly a¡ect the activity of L-galactosidase (Fig. 1B).
These results demonstrate that halothane has no e¡ect on
basal transcription but speci¢cally inhibits HRE-driven gene
transcription.
3.2. Halothane blocks hypoxia-induced HIF-1K protein
expression
The biological activity of HIF-1 is determined by the pro-
tein expression and transcriptional activity of the HIF-1K sub-
unit in Hep3B cells [3]. We exposed Hep3B cells to hypoxia to
examine whether halothane a¡ects HIF-1K protein expression.
0.5% halothane partially suppressed the induction of HIF-1K
expression in response to hypoxia (Fig. 2A, lane 1). 1% or 2%
halothane almost completely suppressed the hypoxia-induced
accumulation of HIF-1K protein (lanes 2 and 3, respectively).
As in the case of HRE-dependent transcription, 1% halothane
is su⁄cient to block the accumulation of HIF-1K protein in
Hep3B cells.
We examined whether this suppressive e¡ect of halothane
on HIF-1 activity was reversible. Hep3B cells were treated
with 1% halothane for 8 h, recovered in air in the absence
of halothane for 4 h and then were exposed to 1% O2 for 4 h.
No signi¢cant di¡erence in HIF-1K protein accumulation was
observed in halothane-treated and halothane-non-treated cells
(Fig. 2B).
3.3. Halothane blocks hypoxia-induced transactivation by
HIF-1K
There are two independent transactivation domains (TADs)
present in HIF-1K. Because it has been shown that steady-
state levels of fusion proteins consisting of the GAL4 DNA
binding domain fused to HIF-1K residues 531^826 are similar
under hypoxic and non-hypoxic conditions (in contrast to
Fig. 1. E¡ect of halothane on hypoxia-induced HIF-1-mediated
gene transcription. Hep3B cells were transfected with pSV40-L-ga-
lactosidase (100 ng), p2.1 or p2.4 (upper panel) (200 ng) or P11w or
P11m (200 ng) (lower panel). Cells were exposed to 20% or 1% O2
for 16 h with or without halothane. The relative fold induction of
luciferase activity was calculated after normalization dividing the lu-
ciferase activity by L-galactosidase activity (A). 10 Wl of lysate was
subjected to L-galactosidase assay (B). The results are the
means þ S.D. and are presented as fold increases in luciferase activ-
ity over the baseline seen at 20% O2 without halothane. #P6 0.05.
RLA, relative luciferase activity; RGA, relative galactosidase activ-
ity.
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endogenous HIF-1K protein expression which is restrictedly
regulated by O2 tension) [9], this GAL4-HIF-1K fusion con-
struct can be used to examine the transcriptional activity of
HIF-1K independently of its protein expression level. 1% hal-
othane inhibited hypoxia-induced transactivation mediated by
GAL4-HIF-1K(531^826) (Fig. 3). pCMV-GAL4-VP16-depen-
dent gene expression was not a¡ected by 1% halothane. This
suggests that neither GAL4 DNA binding activity nor the
basal transcriptional machinery was a¡ected by halothane.
Taken together with data in Fig. 1, the data also indicate
that luciferase activity is not a¡ected by halothane in our
experimental system. Thus, halothane speci¢cally inhibits hyp-
oxia-induced HIF-1K TAD function.
3.4. Halothane blocks CoCl2- or DFX-induced HIF-1 activation
As in the case of hypoxia, CoCl2 and an iron chelator,
DFX, have been established to activate HIF-1 by blocking
the interaction of HIF-1K with von Hippel^Lindau tumor
suppressor protein (VHL) [16^19]. We examined whether hal-
othane a¡ected CoCl2- or DFX-induced HIF-1 activation. As
shown in Fig. 4A, halothane suppressed CoCl2- or DFX-in-
duced HIF-1K protein accumulation. In addition, halothane
suppressed CoCl2- or DFX-induced HRE-dependent gene ex-
pression (Fig. 4B).
4. Discussion
In this report, we have shown that halothane is a reversible
suppressor of HIF-1 activity within a range of clinically rele-
vant doses. Our data have clearly demonstrated that halo-
thane blocked luciferase gene expression driven by an HRE
from either the ENO1 or VEGF gene and that it blocked both
HIF-1K protein accumulation and transactivation mediated
by HIF-1K. Halothane did not signi¢cantly a¡ect luciferase
or L-galactosidase enzymatic activity directly. Although there
are reports that volatile anesthetics including halothane inhib-
it ¢re£y luciferase activity directly in vitro [20], data in Figs. 1
and 3 demonstrated that our experimental system was not
a¡ected by direct e¡ects on luciferase protein.
HIF-1 is expressed in the cells and tissues of mammals. The
HIF-1L subunit is also a partner for the arylhydrocarbon
receptor and the bHLH-PAS proteins and is abundantly ex-
pressed independently of oxygen tension. In contrast, HIF-1K
cannot be detected unless cells are challenged by hypoxia.
Above a critical intracellular oxygen tension, HIF-1K is rap-
idly degraded in proteasomes after its ubiquitination [3]. HIF-
1K contains an oxygen-dependent degradation domain within
which is a highly conserved region containing a binding site
for VHL [3]. VHL organizes the assembly of a complex that
activates a ubiquitin E3 ligase, which then ubiquitinates HIF-
1K, targeting it for degradation. Besides hypoxia, HIF-1 can
also be induced by transition metal cations such as cobalt and
by reagents that chelate iron [3]. Three recent reports pro-
posed that a proline residue of HIF-1K is hydroxylated by a
putative proline hydroxylase which requires oxygen and iron
for its activation and that this modi¢cation plays a critical
role in ubiquitination of HIF-1K under normoxic conditions
[17^19]. Remarkably, halothane suppressed hypoxia-, CoCl2-
or DFX-induced HIF-1K protein accumulation. Halothane
in£uences enzymatic activities of heme proteins including ni-
tric oxide synthase and certain subtypes of NADPH oxidase
[21,22].
Two gaseous molecules, nitric oxide and carbon monoxide,
suppress hypoxia-induced HIF-1K protein accumulation and
HIF-1K transactivation [23^25]. HIF-1K activation by treat-
ment with CoCl2 or DFX is also blocked by NO donors.
Fig. 2. E¡ects of halothane on hypoxia-induced HIF-1K protein ex-
pression. A: Hep3B cells were exposed to 20% or 1% O2 with or
without halothane for 4 h before nuclear extract preparation. 30-Wg
aliquots were subjected to Western blotting. B: Hep3B cells were
exposed to 1% halothane for 8 h and recovered in air for 4 h (lanes
1 and 3). The treated cells were exposed to 1% (lane 3) or 20% O2
(lane 1) for 4 h, harvested, and 30 Wg of nuclear extracts was sub-
jected to Western blotting.
Fig. 3. E¡ects of halothane on hypoxia-induced HIF-1K TAD func-
tion. Construct pGAL4-HIF-1K(531^826) was analyzed for its abil-
ity to transactivate reporter gene ptk-GALpx3-LUC. Hep3B cells
were co-transfected with pGAL4-HIF-1K(531^826) (100 ng), ptk-
GALpx3-LUC (100 ng), and pSV40-L-galactosidase (100 ng). Cells
were exposed to 20% O2, or 1% O2 for 16 h and then harvested.
The results are the means þ S.D. and are presented as fold increases
in luciferase activity over the baseline seen at 20% O2 without treat-
ment with halothane. #P6 0.05. RLA, relative luciferase activity.
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Interestingly, certain types of NO donors such as NOC-18
and GSNO can also activate HIF-1 under non-hypoxic con-
ditions [26^28]. As shown in this report, halothane does not
induce HIF-1 activation under non-hypoxic conditions.
Therefore, halothane may block HIF-1 activation by di¡erent
molecular mechanisms from those involving NO and CO.
In in situ rat liver HIF-1K protein is expressed predomi-
nantly in the perivenous zone, in which O2 concentrations
range from 30 to 35 mm Hg (4^5%) [29,30]. Taking account
of the evidence that HIF-1 activation occurs at less than 5%
O2 [31], the expression pattern may be correlated with the O2
concentration gradient in the liver sinusoids. The switch from
aerobic to anaerobic metabolism during chronic hypoxia is
regulated by HIF-1 and maintenance of cellular lactic acid
concentration and cellular proliferation under hypoxic condi-
tions requires HIF-1 [32]. In the liver, cell proliferation during
regeneration after partial hepatectomy starts from the peri-
portal areas [33]. Taken together with its essential role in
the metabolic switch, HIF-1 may play a critical role in regen-
eration after partial liver resection. Because HIF-1 activation
is observed within 2 min after onset of hypoxia [34], anesthe-
sia with halothane several hours during operation may a¡ect
metabolic function and liver regeneration.
In summary, we have shown that halothane reversibly
blocks cellular hypoxic responses mediated by HIF-1. Because
the involvement of HIF-1 in hypoxic response is not limited to
the liver, investigations of the e¡ects of halothane in other
tissues or organs, such as brain, kidney, lung and blood ves-
sels, and of other anesthetics both volatile and those admin-
istered intravenously are indicated. Those studies may provide
new insights into the mechanisms by which HIF-1 activity is
regulated by cellular O2 concentrations. In addition, they may
indicate the involvement of HIF-1 inhibition in the patho-
physiology of halothane-induced hepatotoxicity.
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